InvestorsHub Logo
Followers 177
Posts 24589
Boards Moderated 13
Alias Born 04/03/2002

Re: None

Thursday, 04/04/2024 2:27:31 PM

Thursday, April 04, 2024 2:27:31 PM

Post# of 27373
$RENB - Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace | NASDAQ https://www.nasdaq.com/press-release/cutting-edge-ai-company-gedicube-and-cyclomics-sign-binding-loi-to-join-forces-and-0

From the article:

A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
Cyclomics’ 4th generation liquid biopsy genomics platform is a truly “Omni-Omic” blood test ready for AI application
GEDiCube’s award-winning AI is developing high-performance biomarker panels for 13 different cancers.
GEDiCube’s partnership with NVIDIA’s Inception program will help expand to multi-modal capabilities by adding imaging.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.